Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab B Cell Depletion in RA
NCT00555542Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2006
- Primary completion
- May 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by The Chinese University of Hong Kong. Primary endpoint: American College of Rheumatology 20% Response at 54 weeks. Started Jul 2006; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00555542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555542.